Incyte Expands Skin Diseases Treatment Partnership in Australia

03:52 AM EDT, 09/21/2026 (MT Newswires) -- Incyte's (INCY) affiliate expanded its partnership with Specialised Therapeutics to commercialize, distribute and register ruxolitinib cream in Australia, Specialised Therapeutics said Sunday. The company said Ruxolitinib cream is approved in Australia to treat non-segmental vitiligo in adults and children ages 12 and older, and mild-to-moderate atopic dermatitis in adults and children ages 2 and older. Under the agreement, Specialised Therapeutics said Incyte will continue to handle development and manufacturing, while it will oversee regulatory submissions, medical affairs, marketing and distribution in Australia.